|
Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team
|
Public Relations |
Press Release |
2025 |
|
National Heart, Lung, and Blood Institute / National Institutes of Health Signs Clinical Trial Agreement with Vascarta Inc. to Perform Phase 1 Clinical Study of VAS-101 in Sickle Cell Disease
|
Sickle Cell Disease |
Press Release |
2025 |
|
Summary of Vascarta Patent Portfolio
|
Sickle Cell Disease |
Press Release |
2025 |
|
Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease
|
Sickle Cell Disease |
Press Release |
2025 |
|
The Scientific Origins Behind Vascarta Inc. and VAS-101 (Vasceptor®)
|
Sickle Cell Disease |
Promotional |
2025 |
|
Vascarta commences Proof of Concept Phase 1 clinical study of VAS-101 in sickle cell disease in the United States
|
Sickle Cell Disease |
Press Release |
2025 |
|
Chatham & Short Hills Magazine
|
Public Relations |
Magazine |
2025 |
|
Vascarta commences a Phase I clinical study of VAS101 in osteoarthritis
|
Osteoarthritis |
Press Release |
2025 |
|
Patented transdermal drug candidate from Vascarta may offer a convenient & cost-effective way to treat sickle cell disease
|
Sickle Cell Disease |
Press Release |
2025 |
|
Geroscience – Salutary effects of transdermal curcumin on multiple indices of health span in rodent models of normal aging and lifespan (2025)
|
Aging |
Published Manuscript |
2025 |
|
PNAS Nexus – Targeting sickle cell pathobiology with novel transdermal curcumin (2025)
|
Sickle Cell Disease |
Published Manuscript |
2025 |
|
Vascarta and CUNY collaborate to improve chemotherapy efficacy and safety
|
Oncology |
Research Collaboration Agreement |
2025 |
|
VAS-101 Enhances Red Blood Cell Preservation
|
Red Blood Cell Health |
Press Release |
2025 |
|
Vascarta Promotional Video
|
Public Relations |
Video |
2024 |
|
Scientific Reports – Biopreservation and reversal of oxidative injury during blood storage by a novel curcumin-based gel formulation (2024)
|
Red Blood Cell Health |
Published Manuscript |
2024 |
|
66th ASH MEETING – Mechanism Based Treatable Targets for Organ Damage and Pain in SCD (2024)
|
Sickle Cell Disease |
Poster Presentation |
2024 |
|
Vascarta Presents Breakthrough Sickle Cell Treatment at ASH Conference
|
Sickle Cell Disease |
Press Release |
2024 |
|
Joel Friedman - Vascarta Article, Einstein Magazine, Winter-Spring 2023
|
Public Relations |
Magazine Article |
2023 |
|
Promising Data for Transdermal Curcumin in Sickle Cell Disease
|
Sickle Cell Disease |
Press Release |
2023 |
|
Novel transdermal curcumin therapeutic preserves endothelial barrier function in a high-dose LPS rat model; ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY 2023, VOL. 51, NO. 1, 33–40)
|
Endothelial Dysfunction |
Published Manuscript |
2023 |
|
Published poster: Mechanism-based Targeting of Sickle Cell Pathobiology and Pain with Novel Transdermal Curcumin
|
Sickle Cell Disease |
Poster Presentation |
2023 |
|
65TH ASH MEETING – MECHANISM BASED TREATABLE TARGETS FOR ORGAN DAMAGE AND PAIN IN SCD (2023)
|
Sickle Cell Disease |
Poster Presentation |
2023 |
|
FDA CBER & Vascarta Research Plan – Mechanistic insights into blood storage lesions and the development of antioxidant countermeasures
|
Red Blood Cell Health |
Research Collaboration Agreement |
2022 |
